Aclaris Therapeutics, Inc. (FRA:8AT)

Aclaris Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 20, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	298	256	67	983	783	227
Market Cap Growth	12.86%	280.97%	-93.15%	25.54%	244.83%	225.67%
Enterprise Value	158	91	-100	753	571	195
Last Close Price	2.71	2.58	0.93	14.88	12.69	5.24
PS Ratio	22.21	14.18	2.38	35.30	131.67	42.84
PB Ratio	2.91	1.71	0.47	5.32	4.51	7.38
P/TBV Ratio	2.91	1.71	0.47	5.51	4.68	9.10
EV/Sales Ratio	11.82	5.06	-	27.04	96.09	36.79
Debt / Equity Ratio	0.02	0.02	0.02	0.01	0.02	0.38
Net Debt / Equity Ratio	-1.37	-1.29	-1.13	-1.15	-1.13	-1.06
Net Debt / EBITDA Ratio	2.51	3.86	1.56	-	3.42	0.83
Net Debt / FCF Ratio	3.84	9.97	2.24	3.34	4.25	1.02
Asset Turnover	0.09	0.09	0.14	0.12	0.04	0.08
Quick Ratio	3.93	3.88	3.86	9.94	8.38	3.69
Current Ratio	3.93	3.99	4.16	10.56	8.94	3.87
Return on Equity (ROE)	-113.23%	-84.46%	-49.88%	-44.01%	-77.33%	-95.12%
Return on Assets (ROA)	-22.98%	-15.72%	-31.67%	-21.04%	-25.38%	-35.87%
Return on Capital Employed (ROCE)	-43.90%	-27.80%	-68.80%	-36.60%	-28.60%	-86.80%
Earnings Yield	-40.53%	-49.76%	-118.96%	-8.28%	-10.21%	-18.37%
FCF Yield	-12.30%	-7.61%	-107.07%	-6.49%	-5.89%	-14.08%
Buyback Yield / Dilution	-62.68%	-10.73%	-7.05%	-14.95%	-33.36%	-2.94%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.